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There has been increasing interest in en bloc resection of bladder tumour (ERBT) as 
an oncologically non-inferior alternative to transurethral resection of bladder tumour 
(TURBT) with fewer complications and better histology specimens. However, there is 
a lack of robust randomised controlled trial (RCT) data for making recommendations. 
 
Objective 
We aimed to develop a consensus statement to standardise various aspects of ERBT 
for clinical practice and to guide future research.  
 
Design, Setting and Participants 
We developed the consensus statement on ERBT using a modified Delphi method. 
First, two systematic reviews were performed to investigate the clinical effectiveness 
of ERBT versus TURBT (effectiveness review), and to identify areas of uncertainty in 
ERBT (uncertainties review). Next, 200 health care professionals (urologists, 
oncologists and pathologists) with experience in ERBT were invited to complete a 
two-round Delphi survey. Finally, a 16-member consensus panel meeting was held to 
review, discuss and re-vote on the statements as appropriate. 
 
Outcome Measurements and Statistical Analysis 
Meta-analyses were performed for RCT data in the effectiveness review. Consensus 
statements were developed from the uncertainties review. Consensus was defined as: 
(1) ≥70% scoring a statement 7-9 AND ≤15% scoring the statement 1-3 (consensus 
agree); OR (2) ≥70% scoring a statement 1-3 AND ≤15% scoring the statement 7-9 
(consensus disagree). 
 
Results and Limitations 
A total of 10 RCTs were identified upon systematic review. ERBT had a shorter 
irrigation time (mean difference -7.24 hours, 95% CI -9.29 - -5.20, I2=85%, p<0.001) 
and lower rate of bladder perforation (Risk ratio [RR] 0.30, 95% CI 0.11-0.83, I2=1%, 
p=0.02) than TURBT, both with moderate certainty of evidence. There were no 
significant differences in recurrences at 0-12 months, 13-24 months or 25-36 months 
(all very low certainty of evidence). A total of 103 statements were developed and 99 
of them reached consensus. In summary: ERBT should always be considered for 
treating non-muscle-invasive bladder cancer; ERBT should be considered feasible 
even for bladder tumours larger than 3cm; Number and location of bladder tumours 
are not major limitations in performing ERBT; The planned circumferential margin 
should be at least 5mm from any visible bladder tumour; After ERBT, additional 
biopsy of the tumour edge or tumour base should not be performed routinely; For the 
ERBT specimen, T1 substage, circumferential and deep resection margins must be 
assessed; It is safe to give single-dose of immediate intravesical chemotherapy, to 
perform second look transurethral resection, and to give intravesical BCG therapy 
after ERBT; In studies of ERBT, both per patient and per tumour analysis should be 
performed for different outcomes as appropriate. Important outcomes for future 
ERBT studies were also identified. A limitation is that as consensus statements are 
brief, concise and binary in nature, areas of uncertainty which are complex in nature 
may not be addressed adequately. 
 
Conclusions 
We have provided the most comprehensive review of the evidence base to date with 
meta-analysis where appropriate and GRADE applied, and mobilized the international 
urology community to develop a consensus statement on ERBT using transparent and 
robust methods. The consensus statement will provide interim guidance for health 
care professionals who practice ERBT and inform researchers on ERBT-related 
studies in the future.  
 
Patient summary 
ERBT is a surgical technique aiming to resect the bladder tumour in one piece. We 
included an international panel of experts to agree on the best practice of ERBT, and 





En bloc resection of bladder tumour (ERBT) was first described by Kitamura et al. in 
1980 [1]. ERBT has three potential benefits in treating non-muscle-invasive bladder 
cancer (NMIBC) when compared to conventional transurethral resection of bladder 
tumour (TURBT). First, bladder tumour is resected in one piece and the tumour 
specimen remains intact for a proper histological assessment. Whether a complete 
resection has been achieved can be ascertained by histological means rather than the 
surgeon’s judgment alone. Second, the resection process is more precise and 
controlled, thus the complication profile, in particular the risk of bladder perforation 
may be reduced. Third, ERBT can avoid tumour fragmentation as in the case of 
conventional piecemeal resection. It can potentially minimize the amount of floating 
tumour cells and reduce the risk of tumour re-implantation.  
 
ERBT upholds the basic principles in cancer surgery and it has gained increasing 
interests globally in the past decade. However, high-quality data is limited to make 
robust recommendations. There is a lack of standardization leading to heterogeneity 
in the clinical and technical aspects of ERBT. It is important to develop a consensus 
statement on ERBT that can serve as a standard reference for health care professionals 
in the future. It will have important implications in our clinical practice as well as 
future studies of ERBT. 
 
  
2. Material and methods 
We developed the consensus statement on ERBT using a modified Delphi method. 
The development process included two systematic reviews, a two-round Delphi 
survey and a face-to-face consensus meeting (Fig.1). 
 
2.1. Systematic reviews  
Two systematic reviews were performed according to the PRISMA guidelines [2] and 
the study protocol was registered on PROSPERO [3]. The ‘effectiveness’ review 
assessed the benefits and harms of ERBT compared to conventional TURBT and 
provided certainty of evidence ratings using the GRADE methodology [4,5]. The 
‘uncertainties’ review identified clinical and technical uncertainties in the area of 
ERBT. The findings of the systematic reviews provided the basis for the statements 
developed for voting in the Delphi survey and consensus meeting. 
 
2.1.1. Search strategy 
A comprehensive literature search to encompass the effectiveness and uncertainties 
reviews was performed using combination of keywords (MeSH terms and free text 
words) related to ‘bladder tumor’, and ‘en bloc resection’/ ‘ERBT’. MEDLINE, 
EMBASE, and Cochrane library (CENTRAL and CDSR) were searched. The search 
strategy was presented in Appendix 1. Additional references were sought from the 
reference lists of the included studies. 
 
2.1.2. Types of studies included 
All randomized and non-randomized comparative studies, reported in journals or 
conference proceedings, were included in the effectiveness review. Single-arm case 
series or case reports were excluded from the effectiveness review but were retained 
for the uncertainties review. There was no cut-off date for the literature search. Only 
articles with English texts were included. Conference proceedings, letters to editors, 
commentaries and international guidelines were included in the uncertainties review.  
 
2.1.3. Assessment of risk of bias  
For the effectiveness review, the risk of bias in RCTs was assessed by using the 
recommended tool in the Cochrane Handbook for Systematic Reviews of Intervention 
[6]. Risk of bias in non-randomised comparative studies was assessed with the same 
tool, with an extra item to assess the risk of findings being explained by confounding. 
This is a pragmatic approach informed by methodological literature pertaining to 
assessing risk of bias in non-randomised studies, and it is the approach adopted in 
systematic reviews commissioned by the EAU guidelines office to inform their 
guidelines [7]. 
 
2.1.4. Data synthesis and statistical analysis 
For the effectiveness review, meta-analysis was performed if there were two or more 
RCTs reporting on the same outcome. Data from RCT conference proceedings were 
included to reduce the risk of publication bias [6]. Reports of the same studies were 
linked together, where the report containing the most complete data and longest 
follow-up were used. Relative risk (RR) and its 95% confidence interval (CI) were 
used to summarise statistic dichotomous data. Mean differences were used to 
summarise continuous data. Some clinical and methodological heterogeneity across 
the studies was suspected and therefore a random effects model was used. Narrative 
synthesis, using the methods outlined in the Centre for Reviews and Dissemination 
handbook, were used to synthesize the results from non-randomised studies [8]. 
Results from non-randomised studies were not included in the quantitative analysis, 
as there may be significant selection bias especially in the context of ERBT. 
Application of GRADE certainty of evidence was done in accordance with the 
GRADE handbook [9].  
 
For the uncertainties review, areas of uncertainties in ERBT were extracted verbatim 
from any of the studies or sources meeting inclusion criteria. The extracted data were 
categorised with reference to the usual management pathway, and grouped under 
domains such as case selection, surgical procedure, post-operative management and 
follow-up schedule. To reduce the data further, statements relating to the same 
concept were subsumed within one statement, resulting in a conceptual map of 
uncertainties identified in the ERBT literature. These statements were then used to 
create positively worded statements which can be agreed or disagreed with, for 
inclusion in the Delphi survey. The statements were discussed within the steering 
group (JYCT, SM, HM, TH, MB) and finalised before proceeding to the Delphi 
survey. 
 
2.2. Two-round Delphi survey 
Delphi survey methods were used to promote anonymity and to control for the 
influence of dominant voices or perceived authoritative voices, yet still provided 
controlled feedback to participants [10].  
 
2.2.1. Conduct of the two-round Delphi survey 
The two-round Delphi survey was conducted using DelphiManager [11]. A total of 
200 urologists, oncologists and pathologists involved in the field of ERBT were 
purposively sampled for expertise and geographical location, to ensure we covered 
adequate breadth of international experience. The steering group provided the names 
of known experts in the field. This was supplemented by inviting the authors of 
studies included in the systematic reviews. Finally, in order to gather opinion from a 
more general perspective, a Twitter advert was promoted using the hashtags #ERBT 
and #UroSoMe [12]. Interested individuals were verified to have personal experience 
in ERBT before they were invited to participate in the online Delphi survey via an 
email providing a link to the study. The link took them to a webpage providing 
information about the aims and objectives of the study, with a further link to a 
registration page. Informed consent was implied if the participant registered to take 
part.  
 
As ERBT is heavily surgery-oriented, a single heterogeneous panel model was used, 
as we did not think it is necessary to look for differences across stakeholder groups 
(i.e. urologists, pathologists and oncologists) [10,13]. Participants were asked to state 
their strength of agreement on a scale of 1 (Strongly disagree) to 9 (Strongly agree). 
There was also an ‘unable to score’ option. Participants were instructed to choose 
‘unable to score’, rather than ‘5’ (neither agree nor disagree) if they felt they did not 
have enough knowledge or expertise on a particular statement, because these two 
concepts are qualitatively different. We made this explicit because this phenomenon 
has been noted as a limitation in other consensus projects [14,15]. During the first 
round, participants could suggest additional items to be incorporated into the second 
round of survey (subjected to review by the steering group). Only those who had 
completed the first-round survey could participate in the second-round survey. In the 
second round, they were reminded of their own round one score and were shown a 
distribution of the group scores across the 1-9 scale for each statement. They were 
allowed to use this information to consider retaining their previous scores or changing 
their scores relative to the field. All voting results were anonymous to minimize bias 
and influence to agree with dominant or authoritative voices. 
 
2.2.2. Definition of consensus and analysis plan 
Consensus is defined as: (1) ≥70% scoring a statement 7-9 AND ≤15% scoring the 
statement 1-3 (consensus agree); OR (2) ≥70% scoring a statement 1-3 AND ≤15% 
scoring the statement 7-9 (consensus disagree). This definition has been used in other 
urology consensus meetings [14-16] and achieves a balance between being over-
inclusive and over-exclusive whilst still allowing a consideration of variance (i.e. 
spread or divergent opinions) [17]. 
 
2.3. Consensus meeting 
A consensus meeting was held to review the statements that reached consensus in the 
Delphi survey, and to discuss in-depth and re-vote on those statements upon which 
there was no consensus. The consensus panel consisted of 16 members, including 12 
urologists, one oncologist, one pathologist, one methodologist (non-voting member) 
and one patient representative. The meeting was chaired by the methodologist with 
experience in chairing consensus meetings and no conflicts of interest regarding 
ERBT. First, the results of the effectiveness review were presented and discussed. 
Next, the two-round Delphi survey results were discussed. Panel members were 
provided with a hard-copy overview of the Delphi voting results for both rounds, 
along with a reminder of their own votes in both rounds. Statements where there was 
clear consensus were reviewed to ensure the results were sensible. Then statements in 
which >5 participants had chosen ‘unable to score’ were reviewed to explore reasons 
for this. Finally, statements not reaching consensus from the Delphi survey were 
discussed in depth before anonymous voting using their own smart devices and the 





3.1 Systematic review and meta-analysis 
The PRISMA flow diagram was shown in Fig. 2. The initial search yielded 669 
records. After removing duplicates, 430 articles were screened based on title and 
abstract. For the effectiveness review, 44 articles were reviewed in full-text. At the 
end of the process, 32 studies (with 39 reports) were included in qualitative synthesis. 
Among them, 10 were RCTs (with 13 reports) [19-31] and they were included in 
quantitative analysis. For the uncertainties review, 151 articles were reviewed in full-
text and included for generation of consensus statements. The studies included in the 
uncertainties review were listed in Appendix 1. 
 
Table 1 summarized the study characteristics of the RCTs. Only data from RCTs were 
extracted for subsequent meta-analysis. Risk of bias assessment of the RCTs was 
presented in Fig. 3. Study characteristics and risk of bias assessment of the non-
randomised studies were presented in Appendix 1. The GRADE summary of findings 
profiles was included in Appendix 1.  
 
3.1.1. Effectiveness review - Outcome measures from RCTs 
ERBT had a longer operative time than TURBT (mean difference 9.07 minutes, 95% 
CI 3.36-14.79, I2=86%, p=0.002; very low certainty evidence). ERBT had a shorter 
irrigation time than TURBT (mean difference -7.24 hours, 95% CI -9.29 - -5.20, 
I2=85%, p<0.001; moderate certainty evidence), but there were no significant 
differences in the catheterisation time (mean difference -0.90 days, 95% CI -2.21-
0.41, I2=97%, p=0.18; low certainty evidence) and hospital stay (mean difference -
1.32 days, 95% CI -2.71-0.06, I2=97%, p=0.06; low certainty evidence). Although 
there was no significant difference in the occurrence of obturator nerve reflex (RR 
0.19, 95% CI 0.03-1.22, I2=79%, p=0.08; very low certainty evidence), ERBT had a 
lower rate of clinical bladder perforation than TURBT (RR 0.30, 95% CI 0.11-0.83, 
I2=1%, p=0.02; moderate certainty evidence). Presence of detrusor muscle in 
specimen was similar between ERBT and TURBT (RR 1.11, 95% CI 0.40-3.11, 
I2=77%, p=0.84; very low certainty evidence). There were no significant differences 
in 0-12 months (RR 0.82, 95% CI 0.56-1.19, I2=12%, p=0.29), 13-24 months (RR 
0.79, 95% CI 0.44-1.42, I2=0%, p=0.43) and 25-36 months (RR 0.89, 95% CI 0.65-
1.22, I2=47%, p=0.47) recurrence rates (all very low certainty evidence). Data was too 
limited for the subgroup comparisons between different modalities of ERBT and 
TURBT. The key findings of the meta-analysis were summarized in Fig. 4, and other 
results were summarized in Appendix 1. 
 
3.1.2. Effectiveness review - Outcome measures from non-randomized studies 
Most studies showed that ERBT had a shorter irrigation time and lower rate of 
bladder perforation than TURBT, and this is line with the RCT data. However, the 
results on the operative time were controversial. Most studies showed that ERBT had 
a shorter catheterization time, shorter hospital stay, lower rate of obturator nerve 
reflex and higher rate of detrusor muscle than TURBT. Most studies also showed 
lower 0-12 months,13-24 months and 25-36 months recurrence rates in favour of 
ERBT. All outcomes were judged to be at low or very low certainty of evidence. The 
results were summarized in Appendix 1. 
 
3.2. Uncertainties review - Generation of consensus statements 
Based on the results of the systematic review, 102 statements were generated for the 
first-round survey. After the first-round survey, one additional statement was added, 
resulting in 103 statements in total for the second-round survey.  
 
The statements were grouped under 8 domains as follows. 
1. Definitions and objectives of ERBT  
2. Case selection  
3. Surgical procedure  
4. Different modalities of ERBT 
5. Reporting of intra-operative findings  
6. Specimen preparation and reporting of histological findings  
7. Post-operative management and follow-up schedule 
8. Data reporting and outcome measures  
 
3.3. Two-round Delphi survey  
In the first-round survey, there were 139 respondents out of 200 invitations (69.5%). 
Among the first-round survey respondents, 123 completed the second-round survey 
(88.5%). There was a wide coverage of respondents globally, with the majority 
practising in Europe and Asia. The majority had more than 10 years of clinical 
practice. 90.2% were urologists, 6.5% were pathologists and 3.3% were oncologists. 
This is reflective of the situation that NMIBC is managed mostly by urological 
surgeons. Table 2 summarizes the characteristics of the Delphi participants 
completing both rounds of survey. After the two-round Delphi survey, consensus was 
reached in 88 out of 103 statements (85.4%).   
 
3.4. Consensus panel meeting 
Table 3 listed the characteristics of the panel members. After the discussion and re-
voting processes, the consensus panel was able to reach consensus in 11 out of 15 
statements. Overall, 99 out of 103 statements (96.1%) reached consensus after the 
whole development process.  
 
3.5. Principal findings of the consensus statement  
Table 4 summarized the results of all statements and consensus status after two 
rounds of survey. Table 5 summarized the statements that were discussed and re-
voted, and their consensus status after the voting session. The final results of the 
consensus statements on ERBT were summarized in Table 6. 
 
3.5.1. Definition and objectives of ERBT  
Removal of bladder tumour in one piece [32] is the most appropriate definition for 
ERBT. The main goals of ERBT are to ensure complete local resection of bladder 
tumour, to ensure proper local staging of the disease, and to reduce the risk of tumour 
re-implantation. Upon ERBT, we must aim to include the detrusor muscle layer in the 
specimen. ERBT should always be considered for treating NMIBC [19,22-26,28-30]. 
However, in cases of muscle-invasive bladder cancer (MIBC) and carcinoma-in-situ 
(CIS) of the bladder, ERBT should not be considered [22,25,26,29]. 
 
3.5.2. Case selection  
3.5.2.1. Size of bladder tumour 
Size of bladder tumour is a major limitation in performing ERBT. Most studies used 
bladder tumour size of 3cm as a cut-off in performing ERBT [19,25,26,33,34]. Upon 
Delphi survey, it was agreed that ERBT is feasible for bladder tumour size of less 
than 3cm. For bladder tumour size of more than 3cm, no consensus was reached upon 
Delphi survey. The panel members agreed that, in such situation, it might be difficult 
to extract the specimen in one piece. However, the resection procedure itself is still 
technically possible [22,29,35-38], and the potential benefits of ensuring proper 
staging and complete resection of NMIBC can still be preserved. Therefore, the panel 
members concluded that ERBT should be regarded as a feasible surgical approach 
even for bladder tumours larger than 3cm.  
 
3.5.2.2. Number of bladder tumours 
Number of bladder tumours is not a major limitation in performing ERBT. Most 
studies used 4 bladder tumours as a cut-off in performing ERBT [39-43]. Upon 
Delphi survey, it was agreed that ERBT is feasible for patients with less than 4 
bladder tumours. For patients with more than 4 bladder tumours, no consensus was 
reached upon Delphi survey. The panel members agreed that, in such situation, it 
might take more time and effort to perform ERBT. However, ERBT is still feasible in 
most of the patients within a reasonable operative time [29,33]. Therefore, the panel 
members concluded that ERBT should be regarded as a feasible surgical approach 
even for patients with more than 4 bladder tumours. 
 
3.5.2.3. Tumour location 
Tumour location is not a major limitation in performing ERBT. Upon Delphi survey, 
it was agreed that ERBT is feasible for bladder tumours located at the posterior wall, 
anterior wall, right lateral wall, left lateral wall, trigone, bladder neck and near the 
ureteric orifice areas. Although there was no consensus reached for bladder tumours 
located at the bladder dome upon Delphi survey, there was a 100% consensus in the 
panel meeting that ERBT is feasible in such tumour location. The panel members 
concluded that, although bladder dome tumours might be more technically difficult to 
resect, by allowing more time for resection and with relevant experiences [38,44], 
ERBT is still a feasible approach in such situations.  
 
3.5.3. Surgical procedure  
As bladder cancer changes can be subtle, a thorough cystoscopic examination must be 
performed before any ERBT [22,34,36,45]. However, the evidence on the use of 
enhanced imaging (narrow-band imaging, Image 1S or photodynamic diagnosis) is 
limited especially in the context of ERBT and no consensus was reached in this 
aspect. The bladder should be distended enough, but not over-distended [29,37], to 
facilitate ERBT while avoiding bladder perforation during the procedure. The planned 
circumferential margin should be marked first to facilitate subsequent ERBT 
[35,37,44,45], and it should be at least 5mm from any visible bladder tumour 
[34,36,37]. The depth of incision should be at the detrusor muscle layer 
[19,22,34,36,37,44,45]. As ERBT specimens can provide comprehensive information 
regarding the depth of tumour invasion and resection margins [33,35,46-48], 
additional biopsy of the tumour base and tumour edge should not be routinely 
performed after ERBT. If bladder tumours are adjacent to each other, en bloc 
resection of the cluster of bladder tumours as a whole can be considered. If the 
bladder tumour is too large, after ERBT, dividing the specimen into 2-3 pieces for 
retrieval [45,49] can be considered. Should there be any technical difficulty being 
encountered upon ERBT, conversion to conventional TURBT should be considered. 
Special extraction methods can be considered in retrieving large ERBT specimens 
[35,49,50]. 
 
3.5.4. Different modalities of ERBT  
It is technically feasible to use monopolar energy [37,48,49], bipolar energy [19-
21,46-48,51], holmium laser [33,48,52], thulium laser [22,29,30,48] and HybridKnife 
(hydrodissection) [24-27,35] to perform ERBT. Monopolar and bipolar ERBT allow 
conversion to piecemeal resection readily when technical difficulty arises. Holmium 
and thulium laser ERBT eliminate the risk of obturator nerve reflex during the 
procedure [22,29,33,44]. There is however a risk of residual disease and under-
staging when we use HybridKnife (hydrodissection) for ERBT due to its nature of 
submucosal elevation [35,53]. 
 
3.5.5. Reporting of intra-operative findings  
The EAU guidelines stated that the operative record of conventional TURBT must 
describe tumour location, appearance, size and multi-focality, all steps of the 
procedure, as well as extent and completeness of resection [54], and these also apply 
to ERBT. In addition, the modality used for ERBT, success of ERBT, the need of 
conversion to conventional TURBT, method of tumour extraction, and any additional 
biopsy of the tumour base and tumour edge must be documented. Any problems 
encountered during the ERBT procedure, including the occurrence of obturator reflex, 
bladder perforation and any difficulty in tumour extraction must be documented. 
 
3.5.6. Specimen preparation and reporting of histological findings  
Every ERBT specimen must be prepared and sent for histological assessment 
separately. The EAU guidelines stated that the pathological report of TURBT 
specimen should specify tumour location, tumour grade and stage, lymphovascular 
invasion, unusual (variant) histology, presence of CIS and detrusor muscle [54], and 
these also apply to ERBT specimens. In addition, the maximal dimension of the 
bladder tumour [36], T1 substage [55-57], circumferential and deep resection margins 
[33,35,46-48] must be assessed. 
 
3.5.7. Post-operative management and follow-up schedule 
It is safe to give single-dose of immediate intravesical chemotherapy 
[19,22,29,33,36,37,44,45], to perform second-look TURBT [39,44], and to give 
intravesical BCG therapy after ERBT [19,33,49]. The indications should follow the 
EAU guidelines recommendation as in the case of conventional TURBT [54]. The 
flexible cystoscopy surveillance protocol after ERBT should also follow the EAU 
guidelines recommendation as in the case of conventional TURBT [54]. In addition, 
upon flexible cystoscopy, the location of tumour recurrence must be documented to 
help differentiate between in-field and out-of-field recurrence [19,34,37]. 
 
3.5.8. Data reporting and outcome measures  
In studies of ERBT, both per patient and per tumour analyses should be performed for 
different outcomes as appropriate [46,47]. Peri-operative outcomes, including 
operative time, obturator nerve reflex, successful en bloc resection rate, need of 
bladder irrigation, duration of urethral catheterization and hospital stay should be 
documented. Severity of complications should be measured using the Clavien-Dindo 
grading system [58]. Complications including bladder perforation, need of blood 
transfusion, ureteric stricture, urethral stricture, urinary tract infection and 
transurethral resection syndrome should be documented. For the histological 
assessment, presence of detrusor muscle, circumferential and deep resection margins 
are important outcomes to measure. Whether adjunct treatments, including post-
operative intravesical instillation of chemotherapy, second-look TURBT and 
intravesical BCG therapy, have been given or performed should be reported. For 
those with second-look TURBT performed, any residual or upstaging of disease 
should be reported. For the oncological outcomes, 3-month recurrence rate, 1-year 
recurrence and progression rates, and 5-year recurrence and progression rates are 
important outcomes to measure.  
  
4. Discussion 
In our effectiveness review, which is the most comprehensive and methodologically 
robust systematic review of the ERBT evidence base to date, we identified 10 RCTs 
comparing ERBT and TURBT, however, only 4 of them [19,22,29,31] were 
published as full-text articles. High-quality data is limited for making robust 
recommendations in ERBT, and this explains why it is important to develop a 
consensus statement to provide the highest level of evidence that we can achieve so 
far, which can serve as a standard reference for health care professionals in the future. 
This consensus statement is the first attempt trying to standardize the management of 
bladder cancer patients with special focus on ERBT. We mobilized the international 
community and used transparent and robust methods to review the evidence, identify 
current uncertainties, and survey expert opinion in an unbiased way, in order to 
provide recommendations for interim practice guidance and a basis to inform the 
research agenda. Health care professionals from different specialties (i.e. urologists, 
oncologists and pathologists) were involved to ensure we had a comprehensive 
collection of opinion across different fields. 
 
4.1. Relevance and impact of study findings on clinical practice and research 
There are several important messages that may impact on our clinical practice. 
Although tumour size has long been recognized as a major limitation, we must 
emphasize that ERBT is a treatment intended for patients with NMIBC. In patients 
with bladder tumours larger than 3cm, there is a reasonable chance of MIBC and 
ERBT should not be considered a definitive treatment when there is a suspicion of 
MIBC. Moreover, it is recognized that the major benefit of ERBT is the ability to 
ensure a complete local resection, and this holds true even when the specimen cannot 
be retrieved in one piece. Therefore, we should still consider ERBT in patients with 
large bladder tumours where NMIBC is considered a possibility. We also offered 
practical solutions on how we can extend the indication of ERBT to patients with 
large bladder tumours. Modified ERBT, e.g. en bloc resection followed by division of 
specimen into 2-3 pieces for retrieval is considered acceptable [45,49]. The use of 
special tumour extraction methods may also facilitate tumour extraction [50],  but we 
need to be aware that the devices being used implied additional costs and were not 
formally approved for such indication, and whether they would lead to increased risk 
of complications such as urethral stricture is unknown. There is an urgent need for 
innovative methods of tumour extraction so as to achieve a true ERBT even for large 
bladder tumours. 
 
ERBT is a surgical approach that aims to uphold the basic oncological principles in 
bladder cancer resection. Although there are different modalities of ERBT, they are 
all technically feasible and there is no data showing superiority of one over the other. 
In ERBT, surgical technique is primary and tools are secondary. Of note, bipolar 
ERBT appears to be the most acceptable modality based on the percentage of 
agreement. This might be explained by its widespread availability, ease and precision 
of resection as well as the allowance of instant conversion to conventional TURBT. 
Although there is a risk of residual disease and understaging when using HybridKnife 
(hydrodissection) for ERBT, this is only theoretical based on its nature of submucosal 
elevation and whether this is genuinely true is unknown.  
 
As ERBT specimens allow assessment of the depth of invasion as well as the 
resection margins, routine additional biopsy of tumour base and tumour edge after 
ERBT is considered unnecessary. If there is any doubt on the completeness of 
resection, addition resection of tumour base and tumour edge can be considered, and 
they should be sent for histological assessment separately. Although pinning of 
circumferential mucosal margin and inking of resection margins in ERBT specimens 
are commonly performed (and possibly a good practice), it is not considered 
mandatory for a proper histological assessment. ERBT specimens also allow more 
precise assessment of the T1 substage. WHO classification of T1a, T1b and T1c 
disease is considered acceptable [57], but more research work will be needed to see 
whether they carry any important prognostic implications in NMIBC after ERBT. 
 
We noticed a significant variation in the reporting of outcome measures across the 
non-randomised studies and RCTs. Data on important outcomes such as the presence 
of detrusor muscle were not readily reported in RCTs. There is also a wide variation 
in the study quality as reflected by our risk of bias assessment. Standardisation on 
data reporting and outcome measures is important to move ERBT forward. Future 
studies on ERBT should consider incorporating the important outcome measures as 
identified by our consensus statement. 
 
4.2. Strengths and limitations 
This consensus statement was developed using a robust and reproducible method 
[10,14-16]. Our systematic reviews were conducted according to the PRISMA 
guidelines [2]. When compared to previous meta-analyses in the literature [59-62], 
our search strategy was most comprehensive, and we only included RCTs in our 
meta-analysis with a proper risk of bias assessment. The GRADE method was used 
for assessing certainty of evidence [9] and this is useful for decision making at many 
levels, including for clinical practice guidelines development. Our uncertainties 
review also provided a solid basis for the survey items being developed. Invitations 
were sent to a large panel of health care professionals purposively sampled from 
across the world. The consensus building process was based on a two-round Delphi 
survey, followed by a consensus panel meeting, where anonymous voting techniques 
were used. All of these improved the internal and external validity of the study 
results. The definition of consensus was also based on previously described 
methodology. 
 
There are several limitations in this study. First, we do recognize the lack of high-
quality studies in ERBT. We were also not able to stratify the results according to 
patient and disease factors. Therefore, some results of the effectiveness review (e.g. 
recurrence rates) have to be interpreted with caution. Second, statements generated 
were brief, concise and binary in nature. Areas of uncertainty which are complex in 
nature may not be addressed adequately. Some terminology (e.g. degree of bladder 
distension) was also difficult to define. Third, most of the participants involved were 
urologists, and they might lack the knowledge regarding certain aspects of ERBT 
such as reporting of histological findings. The statements generated had an extensive 
coverage of every surgical aspect of ERBT. Even urologists may not have sufficient 
personal experience to vote in every statement (e.g. different modalities of ERBT).  
Fourth, we recognized there was a strong representation from Europe and Asia in the 
Delphi survey. This may represent a selection bias from purposive sampling and the 
results may not be applicable in regions outside Europe and Asia. On the other hand, 
it may reflect a genuine situation that ERBT is much more commonly practised in 
Europe and Asia. 
 
4.3. Future directions of ERBT 
Whether ERBT should replace conventional TURBT as the standard of care will 
require more results from high-quality RCTs. In our systematic review, we noticed 
that a number of RCTs have been presented but not fully published. Proper reporting 
according to the CONSORT statement is strongly encouraged [63]. There are also a 
number of on-going RCTs with clinically important primary outcomes. The EB-StaR 
study is a multi-centre study comparing the 1-year recurrence rate between bipolar 
ERBT and bipolar conventional TURBT for patients with bladder tumour size of less 
than 3cm [64]. There are two RCTs comparing between laser ERBT and conventional 
TURBT with the primary outcome of residual tumour upon second TURBT [65,66]. 
There is another RCT investigating the presence of detrusor muscle in the specimen, 
which may serve as a surrogate marker for the quality of resection [67].  
 
One of the major criticisms of ERBT is the inability to retrieve large bladder tumours 
in one piece. Acknowledging the benefit of ensuring a complete resection, we should 
accept modified approaches of ERBT (e.g. ERBT followed by retrieval of bladder 
tumour in several pieces [45,49], piecemeal resection of the exophytic part of bladder 
tumour followed by en bloc resection of the tumour base [68], etc.). Moreover, ERBT 
is focused on patients with NMIBC (presumably smaller in size in most cases), so a 
true ERBT is still feasible for the majority of the patients. An exploratory study 
investigating the role of modified ERBT for patients with bladder tumour size of more 
than 3cm is currently under way [69]. 
 
Although ERBT is a promising surgical technique for NMIBC, the learning curve of 
ERBT and whether it can be easily generalized is an important issue to address. More 
effort will be needed for proper education and training globally. With the foundation 
of the consensus statement, a prospective international registry study on ERBT is 
planned. This will provide us more insights on the generalisability and practicality of 
implementing ERBT in our clinical practice. Long-term real world data will also be 
useful in determining the true value of ERBT. We believe oncological principles exist 
for good reasons, and our group will continue to work together and contribute to the 
development of ERBT in a collaborative manner. 
  
5. Conclusions 
A consensus statement for ERBT has been developed, and it has a comprehensive 
coverage regarding every aspect of ERBT. The findings will guide and inform health 
care professionals about the routine clinical practice of ERBT, and has important 
implications regarding future studies of ERBT. The consensus statement will serve as 
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Two systematic reviews 
- The ‘effectiveness review’ 
o Clinical effectiveness of ERBT and TURBT were compared 
- The ‘uncertainties review’ 
o 102 statements on ERBT were developed 
o The statements were grouped under 8 domains 
Two-round Delphi survey 
- First round 
o 139/200 respondents 
o Added one statement, i.e. 103 statements for second round 
- Second round 
o 123/139 respondents 
o 88/103 statements reached consensus after the two-round survey 
Consensus meeting 
- Face-to-face consensus meeting involving 16 panel members 
- Statements that reached consensus in the two-round Delphi survey were 
reviewed 
- Statements that did not reach consensus in the two-round Delphi survey 
were discussed in-depth and re-voted 





Fig. 2 - PRISMA flow diagram. 
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Fig. 4 - Key findings of the meta-analysis results from randomised controlled trials.  
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Table 1. Study characteristics of included randomised controlled trials. 






Balan et al. (2018), 
Geavlete et al. (2018) 
and Geavlete et al. 
(2019) a 
Romania NMIBC 
1-3 cm in diameter  
No solid sessile tumours 
Not located at bladder neck or 
involving the ureteral orifice 
Bipolar ERBT vs 
Monopolar TURBT 
90 45  45   
Chen et al. (2015) China Primary NMIBC  
No suspicion of MIBC 
No serious heart, lung or brain 
conditions 
Thulium laser ERBT vs 
TURBT b 
142 71 71 
Cheng et al. (2016) China NMIBC  HybridKnife ERBT vs 
TURBT b 
75 38 37 
Gakis et al. (2017) Germany NMIBC 
Tumour size >5mm  
 
HybridKnife ERBT vs 
TURBT b 
115 56 59 
Hu et al. (2017) and Hu 
et al. (2018) a 
China Primary NMIBC  
Not CIS  
Not >3cm and not <1cm in 
diameter 
Not more than 5 tumours 
HybridKnife ERBT vs 
TURBT b 
93 46 47 
Kufner et al. (2014) Germany Superficial papillary bladder 
tumour  
HybridKnife ERBT vs 
TURBT b  
16 7 9 
Li et al. (2014) China NMIBC  ERBT b vs TURBT b 158 80 78 
Liu et al. (2013) China Newly diagnosed NMIBC 
Not urothelial papillomas 
Not MIBC or CIS 
No upper urinary tract tumours 
No extravesical extension, 
lymphatic metastasis or 
invasion of adjacent organs  
Thulium laser ERBT vs 
Monopolar TURBT  
120 64 56 
Ruffo et al. (2017) Italy Newly diagnosed NMIBC  
 
Thulium laser ERBT vs 
Monopolar TURBT 
54 30 24 
Zhang et al. (2015) China Primary NMIBC 
Not inverted papilloma 
No extravesical extension, 
lymph node metastasis or 
adjacent organ invasion  
No upper urinary tract tumours 
Excluded patients who could 
not tolerate general anaesthesia 
No severe cardiovascular or 
pulmonary disease, or 
disturbance of blood 
coagulation contradicting 
operation 
Thulium laser ERBT vs 
Bipolar TURBT 
292 149 143 
CIS: Carcinoma in-situ; ERBT: En bloc resection of bladder tumour; MIBC: Muscle-invasive bladder cancer; NMIBC: Non-muscle-invasive bladder 
cancer; TURBT: Transurethral resection of bladder tumour. 
a Same study with numerous reports; report with the most complete data and longest follow-up was presented  
b Unknown energy source 
 
 Round 1  
N (%) 




 Africa 4 (2.9%) 2 (1.6%) 
 Asia  70 (50.4%) 62 (50.4%) 
 Australia/New Zealand 2 (1.4%) 2 (1.6%) 
 Europe  53 (38.1%) 48 (39.0%) 
 North America 3 (2.2%) 2 (1.6%) 
 South America 7 (5.0%) 7 (5.7%) 
Years of practice   
 1-5 15 (10.8%) 14 (11.4%) 
 6-10 37 (26.6%) 33 (26.8%) 
 11-15 41 (29.5%) 36 (29.3%) 
 16-20 26 (18.7%) 23 (18.7%) 
 21-25 12 (8.6%) 9 (7.3%) 
 26-30 5 (3.6%) 5 (4.1%) 
 >30 3 (2.2%) 3 (2.4%) 
Specialty   
 Oncologist  6 (4.3%) 4 (3.3%) 
 Pathologist  8 (5.8%) 8 (6.5%) 
 Urologist  125 (89.9%) 111 (90.2%) 
Total 139 (100%) 123 (100%) 
 
Table 2. Characteristics of the Delphi participants who completed both rounds of 
survey. 
 
Name Role Representing body / institution 
Steven MacLennan  Chair (Methodologist) University of Aberdeen, United Kingdom 
Darren Poon  Oncologist The Chinese University of Hong Kong, Hong Kong, China 
Fernand Lai  Pathologist The Chinese University of Hong Kong, Hong Kong, China 
Chow Wing-Kie Patient New Territories East Cluster Bladder Cancer Support Group, Hong Kong, China 
Alberto Breda  Urologist Fundacion Puigvert, Universitat Autonoma de Barcelona, Spain 
Bernard Malavaud  Urologist Institut Universitaire du Cancer, France 
Edmund Chiong  Urologist National University Hospital, National University Health System, Singapore 
Hugh Mostafid  Urologist Royal Surrey County Hospital, United Kingdom 
Jeremy Teoh  Urologist The Chinese University of Hong Kong, Hong Kong, China 
Jun Miki  Urologist Jikei University School of Medicine, Japan 
Lee Hsiang-Ying  Urologist Kaohsiung Municipal Ta-Tung Hospital, Taiwan 
Lee Lui-Shiong  Urologist Sengkang General Hospital, Singapore General Hospital, Singapore 
Marek Babjuk  Urologist Hospital Motol, Charles University, Czech Republic; Medical University of Vienna, Austria. 
Mario Kramer  Urologist University Clinic of Schleswig-Holstein, Campus Luebeck, Germany 
Thomas Herrmann  Urologist Spital Thurgau AG, Switzerland; Hanover Medical School (MHH), Germany 
Wei Yong  Urologist First Affiliated Hospital of Fujian Medical University, Fuzhou, China 
 
Table 3. Panel members of the consensus meeting. 
Table 4. Summary of statements and consensus status after two rounds of Delphi survey. 
 
Domains and statements 

























Definitions and objectives of ERBT 
            
1 Removal of bladder tumour in one 
piece is the most appropriate 
definition for ERBT 
3.6% 9.4% 87.0% 139 1 Agree 0.8% 6.5% 92.7% 123 0 Agree 
2 The depth of ERBT must include 
the detrusor muscle layer in the 
specimen 
5.8% 9.4% 84.8% 139 1 Agree 4.1% 7.3% 88.6% 123 0 Agree 
3 One of the main goals of ERBT is 
to ensure complete local resection 
of bladder tumour 
0.7% 3.6% 95.7% 139 1 Agree 0.8% 0.8% 98.4% 123 0 Agree 
4 One of the main goals of ERBT is 
to ensure proper local staging of the 
disease 
0.7% 0% 99.3% 139 2 Agree 1.6% 0% 98.4% 123 1 Agree 
5 One of the main goals of ERBT is 
to reduce the risk of tumour re-
implantation 
8.8% 14.6% 76.6% 139 2 Agree 4.1% 15.7% 80.2% 123 2 Agree 
6 ERBT should always be considered 
for treatment of non-muscle-
invasive bladder cancer 
8.8% 24.8% 66.4% 139 2 Not reached 4.9% 17.2% 77.9% 123 1 Agree 
7 ERBT should be considered for 
treatment of muscle-invasive 
bladder cancer 
53.7% 26.5% 19.9% 139 3 Not reached 63.9% 19.7% 16.4% 123 1 Not reached 
8 ERBT should be considered to treat 
carcinoma in-situ of the bladder to 
optimize subsequent treatment 
48.1% 31.1% 20.7% 139 4 Not reached 56.3% 26.1% 17.6% 123 4 Not reached 
Case selection 
            
9 Size of bladder tumour is a major 
limitation in performing ERBT 
8.8% 6.6% 84.6% 139 3 Agree 9.2% 3.3% 87.5% 122 2 Agree 
10 ERBT is feasible for patients with 
bladder tumour size of less than 
3cm 
2.2% 4.4% 93.3% 139 4 Agree 1.7% 1.7% 96.6% 122 3 Agree 
11 ERBT is feasible for patients with 
bladder tumour size of more than 
3cm 
21.1% 41.4% 37.6% 139 6 Not reached 15.3% 37.3% 47.5% 122 4 Not reached 
12 Number of bladder tumours is a 
major limitation in performing 
ERBT 
36.5% 29.9% 33.6% 139 2 Not reached 38.3% 17.5% 44.2% 122 2 Not reached 
13 If tumour size is not an issue, 
ERBT is feasible for patients with 
7.4% 13.3% 79.3% 139 4 Agree 5.0% 5.0% 89.9% 122 3 Agree 
less than 4 bladder tumours 
14 If tumour size is not an issue, 
ERBT is feasible for patients with 
more than 4 bladder tumours 
18.8% 34.6% 46.6% 139 6 Not reached 15.1% 21.8% 63.0% 122 3 Not reached 
15 Tumour location is a major 
limitation in performing ERBT 
20.9% 23.1% 56.0% 139 5 Not reached 16.1%b 12.7% 71.2% 122 4 Not reached 
16 ERBT is feasible for bladder 
tumour located at the posterior wall 
3.0% 5.9% 91.1% 139 4 Agree 1.7% 0.8% 97.5% 122 4 Agree 
17 ERBT is feasible for bladder 
tumour located at the anterior wall 
14.9% 26.9% 58.2% 139 5 Not reached 12.8% 14.5% 72.6% 122 5 Agree 
18 ERBT is feasible for bladder 
tumour located at the right lateral 
wall 
0.7% 5.9% 93.3% 139 4 Agree 0% 3.4% 96.6% 122 4 Agree 
19 ERBT is feasible for bladder 
tumour located at the left lateral 
wall 
1.5% 5.9% 92.6% 139 4 Agree 0% 3.4% 96.6% 122 4 Agree 
20 ERBT is feasible for bladder 
tumour located at the trigone 
2.2% 8.1% 89.6% 139 4 Agree 0.8% 2.5% 96.6% 122 4 Agree 
21 ERBT is feasible for bladder 
tumour located at the bladder dome 
17.8% 30.4% 51.9% 139 4 Not reached 16.9% 22.0% 61.0% 122 4 Not reached 
22 ERBT is feasible for bladder 
tumour located at the bladder neck 
13.4% 15.7% 70.9% 139 5 Agree 10.3% 7.7% 82.1% 122 5 Agree 
23 ERBT is feasible for bladder 
tumour located near the ureteric 
orifice 
11.2% 17.2% 71.6% 139 5 Agree 7.6% 9.3% 83.1% 122 4 Agree 
Surgical procedure 
            
24 A thorough cystoscopic 
examination must be performed 
before any ERBT 
3.0% 3.8% 93.2% 137 4 Agree 0.8% 0% 99.2% 122 3 Agree 
25 Narrow-band imaging, Image 1S or 
photodynamic diagnosis must be 
considered to enhance bladder 
cancer detection before ERBT 
19.5% 30.9% 49.6% 137 14 Not reached 14.4% 26.1% 59.5% 122 11 Not reached 
26 The bladder should be distended 
enough to facilitate ERBT 
12.7% 22.4% 64.9% 137 3 Not reached 9.2% 11.8% 79.0% 122 3 Agree 
27 The bladder should not be over-
distended to avoid bladder 
perforation upon ERBT 
4.6% 10.7% 84.7% 137 6 Agree 4.3% 5.1% 90.6% 122 5 Agree 
28 The planned circumferential margin 
should be marked first to facilitate 
subsequent ERBT 
4.5% 14.4% 81.1% 137 5 Agree 1.7% 6.8% 91.5% 122 4 Agree 
29 Upon ERBT, the planned 
circumferential margin should be at 
least 5mm from any visible bladder 
tumour 
7.6% 18.2% 74.2% 137 5 Agree 3.4% 11.0% 85.6% 122 4 Agree 
30 Upon ERBT, the incision should be 
made deep into the detrusor muscle 
layer 
12.9% 12.1% 75.0% 137 5 Agree 11.1% 6.8% 82.1% 122 5 Agree 
31 After ERBT, additional biopsy of 
the tumour base should be 
performed routinely 
39.8% 24.1% 36.1% 137 4 Not reached 45.8% 17.8% 36.4% 122 4 Not reached 
32 After ERBT, additional biopsy of 
the tumour edge should be 
performed routinely 
47.3% 27.5% 25.2% 137 6 Not reached 62.4% 21.4% 16.2% 122 5 Not reached 
33  If bladder tumours are adjacent to 
each other, en bloc resection of the 
cluster of bladder tumours as a 
whole can be considered 
3.0% 8.3% 88.6% 137 5 Agree 1.7% 3.4% 94.9% 122 4 Agree 
34 If the size of bladder tumour is too 
big, after ERBT, dividing the 
specimen into 2-3 pieces for 
retrieval can be considered 
12.2% 22.1% 65.6% 137 6 Not reached 8.5% 12.8% 78.6% 122 5 Agree 
35 Should there be any technical 
difficulty being encountered upon 
ERBT, conversion to conventional 
TURBT should be considered 
1.5% 3.0% 95.5% 137 3 Agree 0.8% 0.8% 98.3% 122 3 Agree 
36 Special extraction methods 
(Endobag, laparoscopic instrument 
through nephroscope, etc.) can be 
considered in retrieving large 
ERBT specimens 
12.2% 11.4% 76.4% 137 14 Agree 8.1% 7.2% 84.7% 122 11 Agree 
Different modalities of ERBT 
            
37 It is technically feasible to use 
monopolar energy for ERBT 
7.5% 20.8% 71.7% 135 15 Agree 5.5% 11.0% 83.5% 122 13 Agree 
38 It is technically feasible to use 
bipolar energy for ERBT 
0.8% 3.2% 96.0% 135 10 Agree 0% 0.9% 99.1% 122 9 Agree 
39 It is technically feasible to use 
holmium laser for ERBT 
1.8% 19.6% 78.6% 135 23 Agree 2.0% 12.9% 85.1% 122 21 Agree 
40 It is technically feasible to use 
thulium laser for ERBT 
2.1% 20.0% 77.9% 135 40 Agree 1.1% 11.1% 87.8% 122 32 Agree 
41 It is technically feasible to use 
HybridKnife (hydrodissection) for 
ERBT 
3.4% 26.1% 70.5% 135 47 Agree 0% 18.1% 81.9% 122 39 Agree 
42 ERBT using monopolar energy 
allows conversion to piecemeal 
resection readily when technical 
difficulty arises 
6.7% 12.6% 80.7% 135 16 Agree 4.5% 6.4% 89.1% 122 12 Agree 
43 ERBT using bipolar energy allows 
conversion to piecemeal resection 
readily when technical difficulty 
0.8% 9.0% 90.2% 135 13 Agree 0% 5.3% 94.7% 122 9 Agree 
arises 
44 Holmium laser eliminates the risk 
of obturator nerve reflex during 
ERBT 
1.0% 20.4% 78.6% 135 32 Agree 0% 8.1% 91.9% 122 23 Agree 
45 Thulium laser eliminates the risk of 
obturator nerve reflex during ERBT 
1.1% 24.7% 74.2% 135 42 Agree 0% 8.9% 91.1% 122 32 Agree 
46 HybridKnife (hydrodissection) is 
the safest modality in performing 
ERBT 
18.1% 50.6% 31.3% 135 52 Not reached 18.2% 57.1% 24.7% 122 45 Not reached 
47 There is a risk of residual disease 
and understaging when we use 
HybridKnife (hydrodissection) for 
ERBT due to its nature of 
submucosal elevation 
11.3% 47.5% 41.3% 135 55 Not reached 7.7% 52.6% 39.7% 122 44 Not reached 
Reporting of intra-operative findings for 
patients undergoing ERBT 
            
48 The modality used for ERBT must 
be documented 
0% 3.0% 97.0% 135 1 Agree 0% 0.8% 99.2% 122 1 Agree 
49 Whether ERBT has been 
successfully performed, or any need 
of conversion to conventional 
TURBT, must be documented 
0% 1.5% 98.5% 135 1 Agree 0% 0.8% 99.2% 122 1 Agree 
50 Whether additional biopsy of the 
tumour base has been performed 
must be documented 
0% 3.7% 96.3% 135 1 Agree 0% 0.8% 99.2% 122 1 Agree 
51 Whether additional biopsy of the 
tumour edge has been performed 
must be documented 
2.2% 4.5% 93.3% 135 1 Agree 0.8% 0.8% 98.3% 122 1 Agree 
52 The EAU guidelines stated that the 
operative record of TURBT must 
describe tumour location, 
appearance, size and multifocality, 
all steps of the procedure, as well as 
extent and completeness of 
resection 
0% 0% 100.0% 135 1 Agree 0% 0% 100.0% 122 1 Agree 
53 Any occurrence of obturator nerve 
reflex and the laterality of obturator 
nerve reflex being encountered 
during ERBT must be documented 
2.3% 18.8% 78.9% 135 2 Agree 0% 9.9% 90.1% 122 1 Agree 
54 Any occurrence of extraperitoneal 
or intraperitoneal bladder 
perforation during ERBT must be 
documented 
0.7% 1.5% 97.8% 135 1 Agree 0.8% 0% 99.2% 122 1 Agree 
55 The method of tumour extraction 
must be documented 
1.5% 4.5% 94.0% 135 1 Agree 0% 0% 100.0% 122 1 Agree 
56 Any difficulty in tumour extraction 
must be documented 
1.5% 6.7% 91.8% 135 1 Agree 0% 4.1% 95.9% 122 1 Agree 
57 Whether the ERBT specimen has 
been divided for extraction must be 
documented 
0.7% 5.2% 94.0% 135 1 Agree 0% 0.8% 99.2% 122 1 Agree 
Specimen preparation and reporting of 
histological findings 
            
58 Every ERBT specimen must be 
prepared and sent for histological 
assessment separately 
1.5% 6.0% 92.5% 135 2 Agree 0.8% 3.3% 95.8% 121 1 Agree 
59 For the ERBT specimen, the 
circumferential mucosal edge must 
be pinned for better orientation and 
better histological assessment of the 
bladder tumour 
7.9% 31.0% 61.1% 135 9 Not reached 5.2% 30.4% 64.3% 121 6 Not reached 
60 For the ERBT specimen, the 
circumferential and deep resection 
margins must be inked to facilitate 
subsequent histological assessment 
14.3% 32.5% 53.2% 135 9 Not reached 8.0% 31.0% 61.1% 121 8 Not reached 
61 For the ERBT specimen, it should 
be serially sectioned at 2mm 
intervals 
3.1% 38.1% 58.8% 135 38 Not reached 0% 29.2% 70.8% 121 32 Agree 
62 The EAU guidelines stated that the 
pathological report of TURBT 
specimen should specify tumour 
location, tumour grade and stage, 
lymphovascular invasion, unusual 
(variant) histology, presence of 
carcinoma-in-situ and detrusor 
muscle 
0% 3.0% 97.0% 135 1 Agree 0% 2.5% 97.5% 121 1 Agree 
63 Upon histological assessment of the 
ERBT specimen, the maximal 
dimension of bladder tumour must 
be documented 
5.8% 22.3% 71.9% 135 14 Agree 2.7% 12.7% 84.5% 121 11 Agree 
64 Upon histological assessment of the 
ERBT specimen, T1 substage must 
be assessed 
1.5% 10.4% 88.1% 135 1 Agree 0.8% 8.3% 90.8% 121 1 Agree 
65 Upon histological assessment of the 
ERBT specimen, circumferential 
resection margin must be assessed 
3.0% 6.7% 90.3% 135 1 Agree 4.2% 2.5% 93.3% 121 1 Agree 
66 Upon histological assessment of the 
ERBT specimen, deep resection 
margin must be assessed 
0.7% 3.0% 96.3% 135 1 Agree 0% 1.7% 98.3% 121 1 Agree 
Post-operative management and follow-up 
schedule 
            
67 It is safe to give single dose of 4.7% 14.2% 81.1% 135 8 Agree 1.7% 6.1% 92.2% 121 6 Agree 
intravesical chemotherapy 
immediately after ERBT 
68 The indications of single-dose of 
intravesical chemotherapy 
immediately after ERBT should 
follow the EAU guidelines 
recommendation as in the case of 
conventional TURBT 
2.3% 9.9% 87.8% 135 4 Agree 1.7% 4.3% 94.0% 121 4 Agree 
69 It is safe to perform second look 
TURBT after the first ERBT 
3.9% 11.6% 84.5% 135 6 Agree 2.5% 6.8% 90.7% 121 3 Agree 
70 The indications of second look 
TURBT after ERBT should follow 
the EAU guidelines 
recommendation as in the case of 
conventional TURBT 
10.0% 14.6% 75.4% 135 5 Agree 7.0% 10.4% 82.6% 121 6 Agree 
71 It is safe to give intravesical BCG 
therapy after ERBT 
3.9% 7.0% 89.1% 135 6 Agree 1.7% 5.1% 93.2% 121 4 Agree 
72 The indications of intravesical BCG 
therapy after ERBT should follow 
the EAU guidelines 
recommendation as in the case of 
conventional TURBT 
1.5% 3.8% 94.7% 135 4 Agree 0% 3.4% 96.6% 121 3 Agree 
73 The flexible cystoscopy 
surveillance protocol after ERBT 
should follow the EAU guidelines 
recommendation as in the case of 
conventional TURBT 
0% 4.5% 95.5% 135 2 Agree 0% 3.4% 96.6% 121 2 Agree 
74c Upon flexible cystoscopy, the 
location of tumour recurrence must 
be documented to help differentiate 
between in-field and out-of-field 
recurrence 
- - - - - - 0.9% 2.6% 96.5% 121 7 Agree 
Data reporting and outcome measures 
            
75 In studies of ERBT, both per 
patient and per tumour analyses 
should be performed for different 
outcomes 
3.8% 10.6% 85.6% 135 3 Agree 1.7% 5.0% 93.3% 121 1 Agree 
76 In studies of ERBT, the operative 
time is an important outcome to 
measure 
10.7% 26.0% 63.4% 135 4 Not reached 8.5% 19.5% 72.0% 121 3 Agree 
77 In studies of ERBT, the presence of 
obturator nerve reflex an important 
outcome to measure 
4.7% 25.0% 70.3% 135 7 Agree 1.8% 16.7% 81.6% 121 7 Agree 
78 In studies of ERBT, the need for 
bladder irrigation is an important 
12.2% 25.2% 62.6% 135 4 Not reached 6.0% 17.9% 76.1% 121 4 Agree 
outcome to measure 
79 In studies of ERBT, the duration of 
urethral catheterization is an 
important outcome to measure 
11.5% 20.8% 67.7% 135 5 Not reached 8.5% 12.0% 79.5% 121 4 Agree 
80 In studies of ERBT, hospital stay is 
an important outcome to measure 
10.5% 21.1% 68.4% 135 2 Not reached 7.6% 10.9% 81.5% 121 2 Agree 
81 In studies of ERBT, the 
complication rate is an important 
outcome to measure 
0% 1.5% 98.5% 135 1 Agree 0% 0.8% 99.2% 121 1 Agree 
82 In studies of ERBT, the Clavien-
Dindo grading system is the 
preferred system to measure the 
severity of complication 
2.3% 9.4% 88.3% 135 7 Agree 1.7% 5.2% 93.0% 121 6 Agree 
83 In studies of ERBT, the need for 
blood transfusion is an important 
outcome to measure 
9.8% 16.7% 73.5% 135 3 Agree 5.9% 12.6% 81.5% 121 2 Agree 
84 In studies of ERBT, the occurrence 
of urethral stricture is an important 
outcome to measure 
11.2% 22.4% 66.4% 135 1 Not reached 6.7% 15.8% 77.5% 121 1 Agree 
85 In studies of ERBT, the occurrence 
of bladder perforation is an 
important outcome to measure 
0% 2.3% 97.7% 135 2 Agree 0% 1.7% 98.3% 121 1 Agree 
86 In studies of ERBT, the occurrence 
of urinary tract infection is an 
important outcome to measure 
12.7% 27.6% 59.7% 135 1 Not reached 6.7% 20.8% 72.5% 121 1 Agree 
87 In studies of ERBT, the occurrence 
of transurethral resection syndrome 
is an important outcome to measure 
14.9% 23.1% 61.9% 135 1 Not reached 12.5% 15.0% 72.5% 121 1 Agree 
88 In studies of ERBT, the occurrence 
of urinary retention is an important 
outcome to measure 
18.7% 29.1% 52.2% 135 1 Not reached 10.0% 28.3% 61.7% 121 1 Not reached 
89 In studies of ERBT, the occurrence 
of ureteric stricture is an important 
outcome to measure 
11.2% 21.6% 67.2% 135 1 Not reached 5.8% 13.3% 80.8% 121 1 Agree 
90 In studies of ERBT, the successful 
en bloc resection rate (i.e. removal 
of bladder tumour in one piece) is 
an important outcome to measure  
0.7% 3.0% 96.3% 135 1 Agree 0% 0.8% 99.2% 121 1 Agree 
91 In studies of ERBT, presence of 
detrusor muscle in the ERBT 
specimen is an important outcome 
to measure 
0.7% 2.2% 97.0% 135 1 Agree 0% 2.5% 97.5% 121 1 Agree 
92 In studies of ERBT, presence of 
clear circumferential resection 
margin in the ERBT specimen is an 
important outcome to measure 
2.3% 5.3% 92.5% 135 2 Agree 3.3% 2.5% 94.2% 121 1 Agree 
93 In studies of ERBT, presence of 
clear deep resection margin in the 
ERBT specimen is an important 
outcome to measure 
0% 3.7% 96.3% 135 1 Agree 0% 0.8% 99.2% 121 1 Agree 
94 In studies of ERBT, whether post-
operative intravesical instillation of 
chemotherapy is given is an 
important outcome to report 
0.8% 15.9% 83.3% 135 3 Agree 0.8% 10.9% 88.2% 121 2 Agree 
95 In studies of ERBT, whether 
second look transurethral resection 
is performed is an important 
outcome to report 
3.0% 9.0% 88.0% 135 2 Agree 1.7% 6.7% 91.6% 121 2 Agree 
96 In studies of ERBT, any residual 
disease is detected upon second 
look transurethral resection is an 
important outcome to report 
1.5% 3.8% 94.7% 135 2 Agree 0% 2.5% 97.5% 121 2 Agree 
97 In studies of ERBT, any upstaging 
of disease is detected upon second 
look transurethral resection is an 
important outcome to report 
1.5% 4.5% 94.0% 135 2 Agree 0% 3.4% 96.6% 121 2 Agree 
98 In studies of ERBT, whether 
intravesical BCG therapy is given is 
an important outcome to report 
3.8% 18.0% 78.2% 135 2 Agree 1.7% 9.2% 89.1% 121 2 Agree 
99 In studies of ERBT, 3-month 
recurrence rate is an important 
outcome to measure 
0.7% 4.5% 94.8% 135 1 Agree 0% 1.7% 98.3% 121 1 Agree 
100 In studies of ERBT, 1-year 
recurrence rate is an important 
outcome to measure 
0% 2.3% 97.7% 135 2 Agree 0% 0.8% 99.2% 121 1 Agree 
101 In studies of ERBT, 1-year 
progression rate is an important 
outcome to measure 
0% 1.5% 98.5% 135 1 Agree 0% 0.8% 99.2% 121 1 Agree 
102 In studies of ERBT, 5-year 
recurrence rate is an important 
outcome to measure 
1.5% 6.7% 91.8% 135 1 Agree 0% 2.5% 97.5% 121 1 Agree 
103 In studies of ERBT, 5-year 
progression rate is an important 
outcome to measure 
1.5% 6.0% 92.5% 135 1 Agree 0% 2.5% 97.5% 121 1 Agree 
EAU = European Association of Urology; ERBT = En bloc resection of bladder tumour; TURBT = Transurethral resection of bladder tumour. 
a In columns showing percentages agree/equivocal/disagree, red shaded cells indicate ≥70%. 
b Green shaded cell indicate ≥15% of disagree despite ≥70% of agree in the same statement. 
c This statement was added after first round of Delphi survey. 
 
Table 5. Summary of the statements that were discussed and re-voted, and their consensus status after the voting session. 















Definitions and objectives of ERBT       
7 ERBT should be considered for treatment of muscle-invasive 
bladder cancer 
80.0% 6.7% 13.3% 15 0 Disagree 
8 ERBT should be considered to treat carcinoma in-situ of the 
bladder to optimize subsequent treatment 
73.3% 13.3% 13.3% 15 0 Disagree 
Case selection 
      
11 ERBT is feasible for patients with bladder tumour size of more than 
3cm 
0.0% 6.7% 93.3% 15 0 Agree 
12 Number of bladder tumours is a major limitation in performing 
ERBT 
86.7% 6.7% 6.7% 15 0 Disagree 
14 If tumour size is not an issue, ERBT is feasible for patients with 
more than 4 bladder tumours 
0.0% 0.0% 100.0% 15 0 Agree 
15 Tumour location is a major limitation in performing ERBT 73.3% 20.0% 6.7% 15 0 Disagree 
21 ERBT is feasible for bladder tumour located at the bladder dome 0.0% 0.0% 100.0% 15 0 Agree 
Surgical procedure 
      
25 Narrow-band imaging, Image 1S or photodynamic diagnosis must 
be considered to enhance bladder cancer detection before ERBT 
20.0% 33.3% 46.7% 15 0 Not reached 
31 After ERBT, additional biopsy of the tumour base should be 
performed routinely 
86.7% 6.7% 6.7% 15 0 Disagree 
32 After ERBT, additional biopsy of the tumour edge should be 
performed routinely 
100.0% 0.0% 0.0% 15 0 Disagree 
Different modalities of ERBT 
      
46 HybridKnife (hydrodissection) is the safest modality in performing 
ERBT 
86.7% 6.7% 6.7% 15 0 Disagree 
47 There is a risk of residual disease and understaging when we use 
HybridKnife (hydrodissection) for ERBT due to its nature of 
submucosal elevation 
0.0% 21.4% 78.6% 14 1 Agree 
Specimen preparation and reporting of histological findings 
      
59 For the ERBT specimen, the circumferential mucosal edge must be 
pinned for better orientation and better histological assessment of 
the bladder tumour 
40.0% 33.3% 26.7% 15 0 Not reached 
60 For the ERBT specimen, the circumferential and deep resection 
margins must be inked to facilitate subsequent histological 
assessment 
20.0% 26.7% 53.3% 15 0 Not reached 
Data reporting and outcome measures 
      
88 In studies of ERBT, the occurrence of urinary retention is an 
important outcome to measure 
13.3% 46.7% 40.0% 15 0 Not reached 
ERBT = En bloc resection of bladder tumour. 
a In columns showing percentages agree/equivocal/disagree, red shaded cells indicate ≥70%. 
 
 
Table 6. Final consensus statements on en bloc resection of bladder tumour. 
 
Domains and statements Consensus stage (Delphi/meeting) 
Direction of consensus 
(Agree/disagree) 
Definitions and objectives of ERBT   
1 Removal of bladder tumour in one piece is the most appropriate definition for ERBT Delphi Agree 
2 The depth of ERBT must include the detrusor muscle layer in the specimen Delphi Agree 
3 One of the main goals of ERBT is to ensure complete local resection of bladder tumour Delphi Agree 
4 One of the main goals of ERBT is to ensure proper local staging of the disease Delphi Agree 
5 One of the main goals of ERBT is to reduce the risk of tumour re-implantation Delphi Agree 
6 ERBT should always be considered for treatment of non-muscle-invasive bladder cancer Delphi Agree 
7 ERBT should be considered for treatment of muscle-invasive bladder cancer Meeting Disagree 
8 ERBT should be considered to treat carcinoma in-situ of the bladder to optimize subsequent treatment Meeting Disagree 
Case selection 
  
9 Size of bladder tumour is a major limitation in performing ERBT Delphi Agree 
10 ERBT is feasible for patients with bladder tumour size of less than 3cm Delphi Agree 
11 ERBT is feasible for patients with bladder tumour size of more than 3cm Meeting Agree 
12 Number of bladder tumours is a major limitation in performing ERBT Meeting Disagree 
13 If tumour size is not an issue, ERBT is feasible for patients with less than 4 bladder tumours Delphi Agree 
14 If tumour size is not an issue, ERBT is feasible for patients with more than 4 bladder tumours Meeting Agree 
15 Tumour location is a major limitation in performing ERBT Meeting Disagree 
16 ERBT is feasible for bladder tumour located at the posterior wall Delphi Agree 
17 ERBT is feasible for bladder tumour located at the anterior wall Delphi Agree 
18 ERBT is feasible for bladder tumour located at the right lateral wall Delphi Agree 
19 ERBT is feasible for bladder tumour located at the left lateral wall Delphi Agree 
20 ERBT is feasible for bladder tumour located at the trigone Delphi Agree 
21 ERBT is feasible for bladder tumour located at the bladder dome Meeting Agree 
22 ERBT is feasible for bladder tumour located at the bladder neck Delphi Agree 
23 ERBT is feasible for bladder tumour located near the ureteric orifice Delphi Agree 
Surgical procedure 
  
24 A thorough cystoscopic examination must be performed before any ERBT Delphi Agree 
25 Narrow-band imaging, Image 1S or photodynamic diagnosis must be considered to enhance bladder 
cancer detection before ERBT 
Meeting Not reached 
26 The bladder should be distended enough to facilitate ERBT Delphi Agree 
27 The bladder should not be over-distended to avoid bladder perforation upon ERBT Delphi Agree 
28 The planned circumferential margin should be marked first to facilitate subsequent ERBT Delphi Agree 
29 Upon ERBT, the planned circumferential margin should be at least 5mm from any visible bladder 
tumour 
Delphi Agree 
30 Upon ERBT, the incision should be made deep into the detrusor muscle layer Delphi Agree 
31 After ERBT, additional biopsy of the tumour base should be performed routinely Meeting Disagree 
32 After ERBT, additional biopsy of the tumour edge should be performed routinely Meeting Disagree 
33 If bladder tumours are adjacent to each other, en bloc resection of the cluster of bladder tumours as a 
whole can be considered 
Delphi Agree 
34 If the size of bladder tumour is too big, after ERBT, dividing the specimen into 2-3 pieces for retrieval 
can be considered 
Delphi Agree 
35 Should there be any technical difficulty being encountered upon ERBT, conversion to conventional 
TURBT should be considered 
Delphi Agree 
36 Special extraction methods (Endobag, laparoscopic instrument through nephroscope, etc.) can be 
considered in retrieving large ERBT specimens 
Delphi Agree 
Different modalities of ERBT 
  
37 It is technically feasible to use monopolar energy for ERBT Delphi Agree 
38 It is technically feasible to use bipolar energy for ERBT Delphi Agree 
39 It is technically feasible to use holmium laser for ERBT Delphi Agree 
40 It is technically feasible to use thulium laser for ERBT Delphi Agree 
41 It is technically feasible to use HybridKnife (hydrodissection) for ERBT Delphi Agree 
42 ERBT using monopolar energy allows conversion to piecemeal resection readily when technical 
difficulty arises 
Delphi Agree 
43 ERBT using bipolar energy allows conversion to piecemeal resection readily when technical difficulty 
arises 
Delphi Agree 
44 Holmium laser eliminates the risk of obturator nerve reflex during ERBT Delphi Agree 
45 Thulium laser eliminates the risk of obturator nerve reflex during ERBT Delphi Agree 
46 HybridKnife (hydrodissection) is the safest modality in performing ERBT Meeting Disagree 
47 There is a risk of residual disease and understaging when we use HybridKnife (hydrodissection) for 
ERBT due to its nature of submucosal elevation 
Meeting Agree 
Reporting of intra-operative findings for patients undergoing ERBT 
  
48 The modality used for ERBT must be documented Delphi Agree 
49 Whether ERBT has been successfully performed, or any need of conversion to conventional TURBT, Delphi Agree 
must be documented 
50 Whether additional biopsy of the tumour base has been performed must be documented Delphi Agree 
51 Whether additional biopsy of the tumour edge has been performed must be documented Delphi Agree 
52 The EAU guidelines stated that the operative record of TURBT must describe tumour location, 
appearance, size and multifocality, all steps of the procedure, as well as extent and completeness of 
resection 
Delphi Agree 
53 Any occurrence of obturator nerve reflex and the laterality of obturator nerve reflex being encountered 
during ERBT must be documented 
Delphi Agree 
54 Any occurrence of extraperitoneal or intraperitoneal bladder perforation during ERBT must be 
documented 
Delphi Agree 
55 The method of tumour extraction must be documented Delphi Agree 
56 Any difficulty in tumour extraction must be documented Delphi Agree 
57 Whether the ERBT specimen has been divided for extraction must be documented Delphi Agree 
Specimen preparation and reporting of histological findings 
  
58 Every ERBT specimen must be prepared and sent for histological assessment separately Delphi Agree 
59 For the ERBT specimen, the circumferential mucosal edge must be pinned for better orientation and 
better histological assessment of the bladder tumour 
Meeting Not reached 
60 For the ERBT specimen, the circumferential and deep resection margins must be inked to facilitate 
subsequent histological assessment 
Meeting Not reached 
61 For the ERBT specimen, it should be serially sectioned at 2mm intervals Delphi Agree 
62 The EAU guidelines stated that the pathological report of TURBT specimen should specify tumour 
location, tumour grade and stage, lymphovascular invasion, unusual (variant) histology, presence of 
carcinoma-in-situ and detrusor muscle 
Delphi Agree 
63 Upon histological assessment of the ERBT specimen, the maximal dimension of bladder tumour must be 
documented 
Delphi Agree 
64 Upon histological assessment of the ERBT specimen, T1 substage must be assessed Delphi Agree 
65 Upon histological assessment of the ERBT specimen, circumferential resection margin must be assessed Delphi Agree 
66 Upon histological assessment of the ERBT specimen, deep resection margin must be assessed Delphi Agree 
Post-operative management and follow-up schedule 
  
67 It is safe to give single dose of intravesical chemotherapy immediately after ERBT Delphi Agree 
68 The indications of single-dose of intravesical chemotherapy immediately after ERBT should follow the 
EAU guidelines recommendation as in the case of conventional TURBT 
Delphi Agree 
69 It is safe to perform second look TURBT after the first ERBT Delphi Agree 
70 The indications of second look TURBT after ERBT should follow the EAU guidelines recommendation Delphi Agree 
as in the case of conventional TURBT 
71 It is safe to give intravesical BCG therapy after ERBT Delphi Agree 
72 The indications of intravesical BCG therapy after ERBT should follow the EAU guidelines 
recommendation as in the case of conventional TURBT 
Delphi Agree 
73 The flexible cystoscopy surveillance protocol after ERBT should follow the EAU guidelines 
recommendation as in the case of conventional TURBT 
Delphi Agree 
74a Upon flexible cystoscopy, the location of tumour recurrence must be documented to help differentiate 
between in-field and out-of-field recurrence 
Delphi Agree 
Data reporting and outcome measures 
  
75 In studies of ERBT, both per patient and per tumour analyses should be performed for different 
outcomes 
Delphi Agree 
76 In studies of ERBT, the operative time is an important outcome to measure Delphi Agree 
77 In studies of ERBT, the presence of obturator nerve reflex an important outcome to measure Delphi Agree 
78 In studies of ERBT, the need for bladder irrigation is an important outcome to measure Delphi Agree 
79 In studies of ERBT, the duration of urethral catheterization is an important outcome to measure Delphi Agree 
80 In studies of ERBT, hospital stay is an important outcome to measure Delphi Agree 
81 In studies of ERBT, the complication rate is an important outcome to measure Delphi Agree 
82 In studies of ERBT, the Clavien-Dindo grading system is the preferred system to measure the severity of 
complication 
Delphi Agree 
83 In studies of ERBT, the need for blood transfusion is an important outcome to measure Delphi Agree 
84 In studies of ERBT, the occurrence of urethral stricture is an important outcome to measure Delphi Agree 
85 In studies of ERBT, the occurrence of bladder perforation is an important outcome to measure Delphi Agree 
86 In studies of ERBT, the occurrence of urinary tract infection is an important outcome to measure Delphi Agree 
87 In studies of ERBT, the occurrence of transurethral resection syndrome is an important outcome to 
measure 
Delphi Agree 
88 In studies of ERBT, the occurrence of urinary retention is an important outcome to measure Meeting Not reached 
89 In studies of ERBT, the occurrence of ureteric stricture is an important outcome to measure Delphi Agree 
90 In studies of ERBT, the successful en bloc resection rate (i.e. removal of bladder tumour in one piece) is 
an important outcome to measure  
Delphi Agree 
91 In studies of ERBT, presence of detrusor muscle in the ERBT specimen is an important outcome to 
measure 
Delphi Agree 
92 In studies of ERBT, presence of clear circumferential resection margin in the ERBT specimen is an 
important outcome to measure 
Delphi Agree 
93 In studies of ERBT, presence of clear deep resection margin in the ERBT specimen is an important Delphi Agree 
outcome to measure 
94 In studies of ERBT, whether post-operative intravesical instillation of chemotherapy is given is an 
important outcome to report 
Delphi Agree 
95 In studies of ERBT, whether second look transurethral resection is performed is an important outcome to 
report 
Delphi Agree 
96 In studies of ERBT, any residual disease is detected upon second look transurethral resection is an 
important outcome to report 
Delphi Agree 
97 In studies of ERBT, any upstaging of disease is detected upon second look transurethral resection is an 
important outcome to report 
Delphi Agree 
98 In studies of ERBT, whether intravesical BCG therapy is given is an important outcome to report Delphi Agree 
99 In studies of ERBT, 3-month recurrence rate is an important outcome to measure Delphi Agree 
100 In studies of ERBT, 1-year recurrence rate is an important outcome to measure Delphi Agree 
101 In studies of ERBT, 1-year progression rate is an important outcome to measure Delphi Agree 
102 In studies of ERBT, 5-year recurrence rate is an important outcome to measure Delphi Agree 
103 In studies of ERBT, 5-year progression rate is an important outcome to measure Delphi Agree 
EAU = European Association of Urology; ERBT = En bloc resection of bladder tumour; TURBT = Transurethral resection of bladder tumour. 
a This statement was added after first round of Delphi survey. 
 
Take home message 
An international collaborative consensus statement on en bloc resection of bladder 
tumour has been developed. The consensus statement serves as a standard reference 
for practising en bloc resection of bladder tumour and conducting future research 
work in this area. 
 1 
Appendix 1. Supplementary data. 
Table of contents Page 
1. Search strategy of the systematic review 2 
2. Study characteristics of included non-randomised studies 3 
3. Risk of bias assessment of included non-randomised studies 7 
4. Other findings of the meta-analysis results from randomised controlled trials 9 
5. Summary of the results from non-randomised studies 10 
6. GRADE summary for randomised controlled trials 14 
7. GRADE summary for non-randomised studies  16 
8. References - List of studies included in the effectiveness review 18 
9. References - List of studies included in the uncertainties review 22 
 
 2 
1. Search strategy of the systematic review 
Database: Embase <1974 to 2019 June 04>, OVID Medline Epub Ahead of Print, In-Process & 
Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to Present, 
EBM Reviews - Cochrane Central Register of Controlled Trials <May 2019>, EBM Reviews - 
Cochrane Database of Systematic Reviews <2005 to June 5, 2019> 
 
Search Strategy: 
1     exp *Urinary Bladder Neoplasms/ or exp *bladder tumor/ (96660) 
2     ((bladder or vesical) adj5 (cancer* or carcin* or malign* or tumor* or tumour* or neoplas* or 
papilloma*)).tw,kw. (133952) 
3     exp *Carcinoma, Transitional Cell/ or *exp transitional cell carcinoma/ (30028) 
4     ((transitional cell or urothelial or urothelium) adj3 (carcinoma* or cancer*)).tw,kw. (50931) 
5     or/1-4 (167520) 
6     (en bloc or ERBT or EBTUR or EBTURBT or RERBT or ETURBT).mp. (25957) 
7     5 and 6 (793) 
8     limit 7 to english language [Limit not valid in CDSR; records were retained] (680) 
9     (exp animals/ or exp animal/ or exp nonhuman/ or exp animal experiment/ or animal model/ 
or animal tissue/ or non human/ or (rat or rats or mice or mouse or swine or porcine or murine or 
sheep or lambs or pigs or piglets or rabbit or rabbits or cat or cats or dog or dogs or cattle or 
bovine or monkey or monkeys or trout or marmoset$1 or basic research or cell lines or in vitro or 
animal model or canine).tw.) not (humans/ or human/ or human experiment/ or (human* or men or 
women or patients or subjects).tw.) (10475381) 
10     8 not 9 (665) 
11     (child/ or Pediatrics/ or Adolescent/ or Infant/ or adolescence/ or newborn/ or (baby or babies 
or child or children or pediatric* or paediatric* or peadiatric* or infant* or infancy or neonat* or 
newborn* or new born* or adolescen* or preschool or pre-school or toddler*).tw.) not (adult/ or 
aged/ or (aged or adult* or elder* or senior* or men or women).tw.) (4140342) 
12     10 not 11 (662) 
13     gall bladder.ti. (4842) 
14     12 not 13 (658)
 3 
2.  Study characteristics of included non-randomised studies 
 
Study Country Study design Eligibility criteria Comparison Total ERBT arm TURBT arm 
Altobelli et al. 
(2016) 
Italy  Retrospective 
cohort study 
Newly diagnosed bladder cancer 
Not locally advanced 
Thulium laser ERBT 
vs TURBT c 
120 60 60 






No distant metastasis 
No upper urinary tract tumours  
No medical conditions 
contradicting surgery 
Greenlight laser 
ERBT vs Monopolar 
TURBT 
158 83 75 





<=3cm in diameter 
<=3 tumours 
No cT2 or higher disease 
No distant metastases 
At least 12 months of follow up 
or until death 
Greenlight laser 
ERBT vs TURBT c 
64 34 30 





Not MIBC or CIS  






193 95 98 








No extravesical extension, 
lymphatic metastasis or invasion 
of adjacent organs 
Holmium laser 
ERBT vs Monopolar 
TURBT 
50 23 27 
Dymov et al. 
(2018) and Kogan 
et al. (2018) a 
Russia Non-randomised 
study b 
cT1 bladder cancer  Thulium laser ERBT 
vs TURBT c 
26 16 10 
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Monopolar EMR + bipolar 
ERBT group:  
>=1.5cm in diameter 
<= 3 tumours 
TURBT group: 
<1.5cm or >6cm in diameter 
>3 tumours 
NMIBC without metastasis 
No neoadjuvant chemotherapy 
and radiotherapy 
Monopolar EMR + 
bipolar ERBT vs 
TURBT c 
70 39 31 






No distant metastasis 
No upper urinary tract tumours 
Thulium laser ERBT 
vs Monopolar 
TURBT 
140 70 70 





Not MIBC ERBT c vs TURBT c 76 26 50 




NMIBC Bipolar ERBT vs 
TURBT c 
31 13 18 
Li et al. 
(2019) 
China  Retrospective 
cohort study 
Primary NMIBC 
No cT2 or higher disease 
Not CIS 
No distant metastasis 
Not >85 years 
Not ASA 4 or above 
Thulium laser ERBT 
vs Bipolar TURBT 
256 136 120 





Excluded specimens without 
muscularis propria 
Greenlight laser 
ERBT vs Bipolar 
TURBT  
158 88 70 




Primary papillary bladder 
tumour 
Single tumour 
>1 cm in diameter 
Thulium laser ERBT 
vs Monopolar 
TURBT 
119 58 61 
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Primary Ta/T1 NMIBC or CIS 
EORTC intermediate risk group 
for recurrence  
ERBT c vs TURBT c 270 39 231 
Mandhani et al. 
(2011), Upadhyay 
et al. (2012) and  






2-4cm in size 
No pedunculated tumours 
No tumour with associated 
hydroureteronephrosis 
No prior TURBT 
Excluded patients with absence 
of detrusor muscle in specimen e 
Monopolar ERBT vs 
Monopolar TURBT 
45 21 24 
Teoh et al. 
(2017a) + Teoh et 





All patients undergoing ERBT 
or TURBT 
Bipolar ERBT vs 
Bipolar TURBT 
154 47 107 







ERBT vs Monopolar 
and bipolar TURBT 
173 64 109 




Primary NMIBC without CIS 
Less than 4.5cm in diameter 
No upper urinary tract tumour 
Vela laser ERBT vs 
TURBT c 
70 26 44 




pT1 bladder cancer ERBT c vs TURBT c 90 18 72 




Primary NMIBC  Monopolar ERBT vs 
Monopolar TURBT 
90 40 50 




Newly diagnosed NMIBC 
Not MIBC 
Not locally advanced 
No distant metastases 
No concomitant benign prostatic 
hyperplasia 
Holmium laser and 
thulium laser ERBT 
vs Monopolar 
TURBT 
97 55 42 





ERBT vs TURBT c 
212 101 111 
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ASA: American Society of Anaesthesiologists; CIS: Carcinoma in-situ; ECOG: Eastern Cooperative Oncology Group; EMR: Endoscopic mucosal 
resection; EORTC: European Organisation for Research and Treatment of Cancer; ERBT: En bloc resection of bladder tumour; MIBC: Muscle-invasive 
bladder cancer; NMIBC: Non-muscle-invasive bladder cancer; TURBT: Transurethral resection of bladder tumour. 
a Same study with numerous reports; report with the most complete data and longest follow-up was presented 
b Nature of study (i.e. retrospective vs prospective) was not mentioned 
c Unknown energy source 
d This is a three-arm study comparing between thulium laser ERBT, holmium laser vaporisation and monopolar TURBT. Data on the holmium laser 
vaporisation group was not presented. 
e This exclusion criteria was only mentioned in Sureka et al. (2014) 
 7 
3. Risk of bias assessment of included non-randomised studies
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4. Other findings of the meta-analysis results from randomised controlled trials 
4.1. Catheterisation time (days) 
 
 
4.2. Hospital stay (days)  
 
 
4.3. Obturator nerve reflex  
 
 
4.4. Presence of detrusor muscle in specimen 
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5. Summary of the results from non-randomised studies  
5.1. Operative time (minutes) 
 
 
5.2. Irrigation time (hours) 
 
 





5.4. Hospital stay (days) 
 
 

















5.6. Bladder perforation 
 
 
5.7. Presence of detrusor muscle in specimen 
 
 










5.9. Recurrence at 13-24 months 
 
 




6. GRADE summary for randomised controlled trials 
Certainty assessment № of patients Effect 
Certainty Importance 
№ of 






10  randomised 
trials  






VERY LOW  
IMPORTANT  
Irrigation time 
2  randomised 
trials  
serious e,f not serious  not serious  not serious  none  102  93  -  MD 7.24 
lower 
(9.29 lower to 





6  randomised 
trials  
serious a,b serious c not serious  not serious  none  304  292  -  MD 0.9 
lower 
(2.21 lower to 





6  randomised 
trials  
serious a,b serious c not serious  not serious  none  300  287  -  MD 1.32 
lower 
(2.71 lower to 




Obturator nerve reflex 
4  randomised 
trials  
serious e,g serious c not serious  very serious h none  15/223 (6.7%)  50/215 (23.3%)  RR 0.19 




fewer to 51 
more)  
⨁◯◯◯ 
VERY LOW  
IMPORTANT  
Bladder perforation 
5  randomised 
trials  
serious a,b not serious  not serious  not serious  none  4/370 (1.1%)  18/353 (5.1%)  RR 0.30 
(0.11 to 0.83)  
36 fewer per 
1,000 
(from 45 






Certainty assessment № of patients Effect 
Certainty Importance 
№ of 






Presence of detrusor muscle in specimen 
3  randomised 
trials  
serious a,b serious c not serious  very serious h none  217/247 (87.9%)  215/242 (88.8%)  RR 1.11 
(0.40 to 3.11)  




1,000 more)  
⨁◯◯◯ 
VERY LOW  
CRITICAL  
 
Recurrence at 0-12 months 
5  randomised 
trials  
serious a,e not serious  not serious  very serious h none  63/322 (19.6%)  72/300 (24.0%)  RR 0.82 
(0.56 to 1.19)  
43 fewer per 
1,000 
(from 106 
fewer to 46 
more)  
⨁◯◯◯ 
VERY LOW  
CRITICAL  
Recurrence at 13-24 months 
2  randomised 
trials  
serious e,f not serious  not serious  very serious h none  17/135 (12.6%)  20/127 (15.7%)  RR 0.79 
(0.44 to 1.42)  
33 fewer per 
1,000 
(from 88 
fewer to 66 
more)  
⨁◯◯◯ 
VERY LOW  
CRITICAL  
Recurrence at 25-36 months 
3  randomised 
trials  
serious e,f not serious  not serious  very serious h none  109/293 (37.2%)  112/277 (40.4%)  RR 0.89 
(0.65 to 1.22)  
44 fewer per 
1,000 
(from 142 
fewer to 89 
more)  
⨁◯◯◯ 
VERY LOW  
CRITICAL  
CI: Confidence interval; RR: Risk ratio; MD: Mean difference 
Explanations 
a. Sequence generation and allocation concealment unclear in most studies  
b. Blinding of outcome assessor unclear in most studies  
c. Important heterogeneity with high I square value  
d. Wide 95% CI  
e. Blinding of outcome assessors unclear in all studies  
f. Allocation concealment unclear in all studies  
g. High risk of bias for allocation concealment in one study and unclear in all others 
h. Very wide 95% CI; contains appreciable benefit and appreciable harm at extremes of the CI.  
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7. GRADE summary for non-randomised studies 
  
Certainty assessment № of patients Effect 
Certainty Importance 
№ of 






15  observational 
studies  
serious a serious b not serious  not serious  none  995 1077 not pooled see comment  ⨁◯◯◯ 
VERY LOW  
IMPORTANT  
Irrigation time 
7  observational 
studies  
serious a not serious  not serious  not serious  none  414  429 not pooled see comment  ⨁◯◯◯ 
VERY LOW  
IMPORTANT  
Catheterisation time 
15  observational 
studies  
serious a serious b not serious  not serious  none  974 1020  not pooled  see comment  ⨁◯◯◯ 
VERY LOW  
IMPORTANT  
Hospital stay 
13  observational 
studies  
serious a not serious  not serious  not serious  none  875  929  not pooled  see comment  ⨁◯◯◯ 
VERY LOW  
IMPORTANT  
Obturator nerve reflex 
12  observational 
studies  




13  observational 
studies  
serious a not serious  not serious  serious c none  864  951  not pooled  see comment  ⨁◯◯◯ 
VERY LOW  
CRITICAL  
Presence of detrusor muscle in specimen 
8  observational 
studies  
serious a not serious  not serious  not serious  none  391 634  not pooled  see comment  ⨁◯◯◯ 
VERY LOW  
CRITICAL  
Recurrence at 0-12 months 
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Certainty assessment № of patients Effect 
Certainty Importance 
№ of 





7  observational 
studies  
serious a not serious  not serious  not serious  none  251 497  not pooled  see comment  ⨁◯◯◯ 
VERY LOW  
CRITICAL  
Recurrence at 13-24 months 
6  observational 
studies  
serious a not serious  not serious  serious d none  378  400  not pooled  see comment  ⨁◯◯◯ 
VERY LOW  
CRITICAL  
 
Recurrence at 25-36 months 
2  observational 
studies  
serious a not serious  not serious  not serious  none  44 51 not pooled  see comment  ⨁◯◯◯ 
VERY LOW  
CRITICAL  
CI: Confidence interval; RR: Risk ratio; MD: Mean difference  
Explanations 
a. Potential for confounding bias (see risk of bias graphs)  
b. Wide variation in estimates between studies; some studies show benefit for TURBT, others show benefit for EBRT  
c. Low event rates contributing to uncertain estimates across studies  
d. Wide confidence intervals across studies, many including appreciable benefit and appreciable harm 
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